[go: up one dir, main page]

MX2013008714A - Metodo para producir compuesto di (arilamino) arilo y producto intermedio sintetico del mismo. - Google Patents

Metodo para producir compuesto di (arilamino) arilo y producto intermedio sintetico del mismo.

Info

Publication number
MX2013008714A
MX2013008714A MX2013008714A MX2013008714A MX2013008714A MX 2013008714 A MX2013008714 A MX 2013008714A MX 2013008714 A MX2013008714 A MX 2013008714A MX 2013008714 A MX2013008714 A MX 2013008714A MX 2013008714 A MX2013008714 A MX 2013008714A
Authority
MX
Mexico
Prior art keywords
arylamino
producing
aryl compound
synthetic intermediate
useful
Prior art date
Application number
MX2013008714A
Other languages
English (en)
Inventor
Kazuyoshi Obitsu
Yutaka Kondoh
Kazuhiro Takeguchi
Ryoki Orii
Takahiro Akiba
Koji Kobayashi
Shun Hirasawa
Yuji Takahama
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2013008714A publication Critical patent/MX2013008714A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Se proporciona un método para producir un compuesto di(arilamino)arilo que tiene actividad inhibidora superior contra las actividades de quinasa de proteína de fusión de EML4-ALK y la proteína EGFR mutante y es útil como un ingrediente activo en composiciones farmacéuticas para el tratamiento del cáncer. El método de producción no incluye etapa de purificación alguna usando cromatografía en columna de gel de sílice o etapa que posiblemente produce un éster de mesilato mutagénico como un subproducto, mejora en gran medida el rendimiento global y es de alto rendimiento y de bajo costo y conveniente para la producción industrial de productos farmacéuticos. También se proporciona un producto intermedio sintético que es útil en el método de producción.
MX2013008714A 2011-01-28 2012-01-27 Metodo para producir compuesto di (arilamino) arilo y producto intermedio sintetico del mismo. MX2013008714A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011016110A JP2012153674A (ja) 2011-01-28 2011-01-28 ジ（アリールアミノ）アリール化合物の製造方法及びその合成中間体
PCT/JP2012/051876 WO2012102393A1 (ja) 2011-01-28 2012-01-27 ジ(アリールアミノ)アリール化合物の製造方法及びその合成中間体

Publications (1)

Publication Number Publication Date
MX2013008714A true MX2013008714A (es) 2013-08-29

Family

ID=46580956

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008714A MX2013008714A (es) 2011-01-28 2012-01-27 Metodo para producir compuesto di (arilamino) arilo y producto intermedio sintetico del mismo.

Country Status (8)

Country Link
US (1) US20130338358A1 (es)
EP (1) EP2669281A4 (es)
JP (1) JP2012153674A (es)
KR (1) KR20140027921A (es)
CN (1) CN103339124A (es)
CA (1) CA2825925A1 (es)
MX (1) MX2013008714A (es)
WO (1) WO2012102393A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105037389B (zh) * 2015-06-09 2017-09-05 丹诺医药(苏州）有限公司 一种利福霉素‑硝基咪唑偶联分子的制备方法
CN113024454B (zh) * 2021-03-25 2022-09-09 浙江工业大学 一种布格替尼中间体的合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE396978T1 (de) * 1999-10-07 2008-06-15 Amgen Inc Triazin-kinase-hemmer
WO2001029011A2 (en) * 1999-10-15 2001-04-26 F. Hoffmann-La Roche Ag Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
US7375222B2 (en) * 2002-02-05 2008-05-20 Astellas Pharma Inc. 2,4,6-Triamino-1,3,5-triazine derivative
EP1565461A2 (en) * 2002-07-11 2005-08-24 Mahesh V. Patel Antibacterial substituted cyanomethyl(ene)piperidinophenyl oxazolidinones, process for their preparation, and pharmaceutical compositions containing them
PT1660458E (pt) 2003-08-15 2012-04-27 Novartis Ag 2,4-pirimidinodiaminas úteis no tratamento de doenças neoplásicas, desordens inflamatórias e do sistema imunitário
TWI389893B (zh) * 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
US20130059855A1 (en) 2010-05-18 2013-03-07 Astellas Pharma Inc. Crystal of di(arylamino)aryl compound

Also Published As

Publication number Publication date
US20130338358A1 (en) 2013-12-19
EP2669281A1 (en) 2013-12-04
EP2669281A4 (en) 2014-01-29
CA2825925A1 (en) 2012-08-02
KR20140027921A (ko) 2014-03-07
WO2012102393A1 (ja) 2012-08-02
CN103339124A (zh) 2013-10-02
JP2012153674A (ja) 2012-08-16

Similar Documents

Publication Publication Date Title
EP3715345A3 (en) Preparation of lfa-1 inhibitor and polymorph thereof
MX2019000536A (es) Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1.
PH12013501758A1 (en) Pyrazolo [1,5-a] pyridines as trk inhibitors
SG10201804791UA (en) 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
PH12015500376A1 (en) Novel bicyclic pyridinones
AU2012204982A8 (en) 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors
AU2012313399A8 (en) 8-ethyl-6-(aryl)pyrido [2,3-d]pyrimidin-7(8H) -ones for the treatment of nervous system disorders and cancer
PH12015500211A1 (en) 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
MX368142B (es) Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab.
MX354373B (es) Proceso para hacer compuestos de ciclopentapirimidina hidroxilada y sus sales.
WO2015019198A3 (en) High potency pancreatin pharmaceutical compositions
MY194873A (en) Fused Bicyclic Heteroaryl Derivatives Having Activity as Phd Inhibitors
CA2878796C (en) Derivatives of pyridinone as inhibitors for tissue transglutaminase
EP2602314A4 (en) MUTANT MICROORGANISM WITH HIGH PRODUCTION OF CADAVERIN AND METHOD FOR PRODUCING CADAVERIN THEREWITH
PH12017500089B1 (en) Aldosterone synthase inhibitors
WO2012080195A3 (en) Polymorphic forms of asenapine maleate and processes for their preparation
HK1222325A1 (zh) 高效的胰酶藥物組合物
MX350443B (es) Proceso para hacer compuestos de aminoácidos.
MX2013008714A (es) Metodo para producir compuesto di (arilamino) arilo y producto intermedio sintetico del mismo.
NZ720805A (en) Processes for the preparation of pyrimidinylcyclopentane compounds
PH12013501665A1 (en) Cathepsin c inhibitors
WO2014021591A3 (ko) 신규한 화합물, 이의 제조방법 및 이를 포함하는 약제학적 조성물
HK1224954A1 (en) High potency pancreatin pharmaceutical compositions